MSH2 mutations were found in 14/28 prostate cancers and this MMR gene has been linked to an expanded spectrum of extracolonic tumors with an increased risk for e.g. urothelial cancer, brain tumors and skin tumors [6, 8–10, 22–24, 28, 29]. The gene discussed is MSH2; the disease is prostate cancer.